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Abstract: Reverse transcription of retroviral genomes into double stranded DNA is a key 
event for viral replication. The very first stage of HIV reverse transcription, the initiation 
step, involves viral and cellular partners that are selectively packaged into the viral 
particle, leading to an RNA/protein complex with very specific structural and functional 
features, some of which being, in the case of HIV-1, linked to particular isolates. Recent 
understanding of the tight spatio-temporal regulation of reverse transcription and its 
importance for viral infectivity further points toward reverse transcription and potentially 
its initiation step as an important drug target. 
Keywords: retrovirus; reverse transcriptase; tRNA 
 
1. Introduction  
Reverse transcription is a central event in the retroviral life cycle, allowing conversion of the single-
stranded genomic RNA into a double-stranded DNA with duplicated long terminal repeats [1]. This is 
achieved by the viral reverse transcriptase (RT) that possesses an RNA- and DNA- dependent DNA 
polymerase activity as well as an endonuclease activity (RNase H) [2]. In both HIV-1 and HIV-2, 
DNA synthesis is initiated by the cellular tRNA3
Lys selectively packaged into the virion [3]. The 
tRNA3
Lys packaging process has been recently unravelled [4]: it involves a number of interactions 
between a Gag/Gag-Pol/vRNA entity and the mitochondrial lysyl-tRNA synthetase (LysRS)/tRNA3
Lys 
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complex. In order for reverse transcription to start, the 3’-terminal 18 nucleotides of the primer tRNA 
are annealed to the complementary viral sequence called the Primer Binding Site (PBS) present in the 
5’-untranslated region (UTR) of the genomic RNA. The precise timing, i.e., during the budding 
process or during maturation of the viral particles, and the number of steps of this process still remain 
to be determined. Formation of the vRNA/tRNA3
Lys complex cannot occur spontaneously at 
physiological temperature since both RNA molecules involved are highly structured. Hence, a viral 
chaperone protein, namely the nucleocapsid protein (NCp) is involved in formation of the HIV-1 
initiation complex of reverse transcription. Recent in vitro data showed that the Viral Infectivity Factor 
(Vif) can partially replace NCp in this function, while the restriction factors APOBEC3G (A3G) and 
A3F have been proposed to inhibit this process. In vitro and in vivo structural probing, mutagenesis, as 
well as replication studies with mutated HIV-1 genomes “forced” to use non-homologous primers 
indicated that the vRNA/tRNA3
Lys interactions are not restricted to the PBS and the 18 3’-terminal 
nucleotides of tRNA3
Lys. However, different groups proposed different interactions, and a consensus 
has yet to be found. Several studies pointed at the structural versatility of the vRNA/tRNA3
Lys 
initiation complex, which might not be conserved among different HIV-1 isolates, and which could 
adopt different two- and three-dimensional structures when using wild type or mutant vRNA templates 
and tRNA3
Lys or other primers. In addition, detailed kinetic studies revealed that the initiation process 
is clearly distinct, at the enzymatic level, from the subsequent elongation step. Our current 
understanding of the initiation complex of HIV-1 reverse transcription has driven some interest in 
using this step as a target for new and specific drugs. This is all the more relevant that recent work has 
highlighted the importance of a tight spatio-temporal regulation, by viral co-factors such as NC, of the 
reverse transcription process, in order for the virus to maintain its infectivity.  
2. Selective packaging of the primer tRNA 
Different retroviruses use different tRNA primers, all of cellular origin (for review, see [3]). Some 
lentiviruses use tRNA1,2
Lys as a pimer for reverse transcription, other use tRNA3
Lys. For HIV-1, 
tRNA3
Lys is the primer and is “selectively” packaged into the viral particles. The “selective” packaging 
refers to the enrichment of the primer tRNA species packaged into the virion by comparison with the 
tRNA population present in the cytoplasm of the infected cell [5]. For example, in particles produced 
from COS7 cells transfected with a HIV-1 proviral DNA, the three major isoacceptors of tRNA
Lys 
(tRNA1,2
Lys and tRNA3
Lys) were preferentially packaged, with the relative concentration of tRNA
Lys 
increasing from 5-6 % in the cell to 50-60 % in the virion, with respect to low molecular weight RNA 
species [6-8]. The number of tRNA
Lys packaged was estimated at 20-25 molecules per virion, with the 
same tRNA3
Lys/tRNA1,2
Lys ratio as in the cell [9]. 
2.1. Structure of tRNA3
Lys  
tRNA3
Lys folds into a classical two-dimensional cloverleaf structure, with acceptor, D, anticodon 
and TC arms (Figure 1a). The three-dimensional structure of tRNA3
Lys has been solved to 3.3 Å 
resolution [10]. As expected, tRNA3
Lys adopts the canonical L-shaped structure that was first 
highlighted in yeast tRNA
Phe (Figure 1b). More importantly, the crystal structure reveals that the 
anticodon loop of human tRNA3
Lys is also perfectly canonical. This contradicts early findings from two Viruses 2010, 2                                       
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different groups, both of which have been studying, by NMR, the solution structure of either an 
undermodified pentanucleotide mimicking the anticodon loop [11] or a much larger oligonucleotide, 
lacking any modifications at positions U34 and A37 [12]. The recently published NMR structure of an 
entire, unmodified, tRNA3
Lys  [13] is in complete agreement with the standard three-dimensional 
structure of a tRNA revealed by X-ray crystallography.  
Figure 1. Secondary (a) and tertiary (b) structures of tRNA3
Lys. 
 
 
2.2. The role of Gag-Pol  
Selection of tRNA
Lys does not depend on viral RNA packaging or maturation of protein precursors 
[9], but requires the unprocessed Gag and Gag-Pol precursors (Figure 2a) [8,14,15]. Since RT interacts 
with primer tRNA3
Lys during reverse transcription, the RT domain of Gag-Pol had been proposed as a 
likely candidate for interacting with tRNA
Lys during selective packaging. Accordingly, the thumb 
domain of RT, shown to interact with tRNA3
Lys in vitro [16-18], was also shown to be important for in 
vivo tRNA packaging [19]. However, the putative implication of the tRNA
Lys anticodon/RT thumb 
interaction [16, 18] has been questioned, since mutations in the RT thumb domain at positions found to 
inhibit the interaction of mature RT with the tRNA3
Lys anticodon in vitro [16], did not affect tRNA3
Lys 
packaging in vivo [19]. A recent model suggests that the interaction between the thumb domain of RT 
within the Gag-pol precursor and tRNA3
Lys only plays a stabilizing role [20].  
2.3. The role of LysRS  
In mammalian cells, LysRS (Figure 2b), which aminoacylates tRNA
Lys, is involved in a multi-
aminoacyl tRNA-synthetase complex comprising 11 enzymes, amongst which only LysRS is found in 
HIV-1 viral particles [21-23]. Notably, about 25 molecules of LysRS are found per virion, a number 
close to that of tRNA
Lys molecules, suggesting the existence of an equimolar complex between these 
two partners. However, and importantly, the incorporation of LysRS into the virion does not require Viruses 2010, 2                                       
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tRNA
Lys packaging [22]. On the other hand, packaging of tRNA
Lys appears to be controlled by LysRS, 
since the amount of primer tRNA that is encapsidated is affected by variations in the number of 
packaged LysRS molecules [23-25]. In addition, RNA interference experiments designed to decrease 
cellular expression of LysRS not only reduced tRNA
Lys packaging, but also viral infectivity [25]. 
Precise mapping revealed that the N-terminal tRNA binding domain of LysRS [26-28], as well as the 
tRNA3
Lys anticodon known to be the major determinant for LysRS recognition [29], is required for 
tRNA packaging. 
Newly synthesized cytoplasmic LysRS was long believed to be the form that is encapsidated into 
the HIV-1 viral particles. Human cytoplasmic and mitochondrial LysRSs result from the same gene 
and are produced by alternative splicing, with the very N-terminus of the two forms being different. 
Production of antibodies able to discriminate between the two proteins pointed to the mitochondrial 
enzyme, in either its pre-mitochondrial or mature form lacking the signal peptide which is cleaved 
during import, as the packaged enzyme [30]. Selective packaging of the mitochondrial form of LysRS 
into the viral particles could be explained by the fact that the cytoplasmic LysRS is involved in the 
multi-aminoacyl tRNA-synthetase complex, which would impede its interaction with HIV or other 
targeting proteins.  
2.4. The packaging complex 
Gag alone was proven to be sufficient for LysRS packaging [22] and Kleiman and co-workers 
mapped the Gag/LysRS interactions in vitro and in vivo. Their results revealed that the two partners 
interact through the dimerisation domains of both LysRS and the CA domain of the Gag precursor 
[31]. Fine mapping indicated that Helix 7 of the LysRS dimerisation domain interacts with Helix 4 of 
the C-terminal dimerisation domain of the CA [32,33]. This interaction is thought to be responsible for 
the selectivity of the packaging process. A weaker interaction between LysRS and the thumb-RNase H 
domain of RT, only observed when both peptides were expressed in the cell, was also reported [20]. 
Based on the data described so far, a model for the packaging complex has been proposed [4,5] (Figure 
2c). In this model, two sub-complexes are involved: 1) the Gag/Gag-Pol/vRNA complex is maintained 
together via well documented Gag/Gag interactions (occurring between the CA, NC and p6 domains 
[34]), Gag-Pol/Gag-Pol interactions (occurring via the PR dimerisation domain [35]) and Gag/vRNA 
interactions [36-40]; 2) the tRNA3
Lys/LysRS complex is maintained together via an interaction between 
the anticodon of tRNA3
Lys and the N-terminal anticodon binding domain of the synthetase [4]. As 
mentioned before, the two complexes interact via a Gag/LysRS interaction that is responsible for the 
selective incorporation of LysRS and hence tRNA3
Lys into the viral particles, whereas the thumb-
RNase H domain of RT within Gag-Pol only stabilizes the interaction [20]. Finally, it was shown that 
although the RT connection domain is dispensable for tRNA packaging, it is required for its annealing 
to the vRNA [41]. 
 Viruses 2010, 2                                       
 
 
217
Figure 2. Partners and model for the tRNA3
Lys packaging complex (a) Organisation of the 
Gag-Pol and Gag precursors. MA: matrix ; CA: capsid ; NC: nucleocapsid ; p6: HIV-1 p6 
protein  ; PR: protease; RT: reverse transcriptase, with its Fingers, Palm, Thumb, 
Connection (Conn.) and RNase H domains; IN: integrase. The dark blue rectangle in the 
capsid domain of the precursors corresponds to the C-terminal helix 4 that was shown to 
interact with lysyl-tRNA synthetase (LysRS) (b) Organisation of LysRS: the anticodon 
(AC) binding domain is located between positions 125 and 207 and the LysRS 
dimerisation (Dz) domain between positions 238 and 266. The two boxes toward the C-
terminus of the protein, between positions 314 and 343 and 544 and 559 are important for 
amino acid recognition. The area highlighted in red (208-259), overlapping the 
dimerisation domain, is involved in binding to the capsid. (c) Model for the packaging 
complex. The purple patch corresponds to the anticodon binding domain and the red patch 
to amino acids 208-259 that interact with the CA domain of Gag.  
 
 
2.5. tRNA3
Lys amino-acylation 
While previous studies indicated that, on the contrary to cellular tRNA
Lys, tRNA
Lys purified from 
virions is uncharged [9], it is not clear whether charged or uncharged tRNA
Lys is initially packaged. It 
was shown that the mature HIV-1 RT was unable to extend acylated tRNA3
Lys and did not increase Viruses 2010, 2                                       
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deacylation [42]. Thus, a possible role of tRNA3
Lys acylation could be to prevent premature initiation 
of reverse transcription [42,43]. The fact that only deacylated tRNA3
Lys was found within viral 
particles does not contradict this assertion, since spontaneaous deacylation of tRNA3
Lys could easily 
occur during the time lapse necessary for virion collection and purification.  
3. Secondary structure of the PBS domain 
Detailed in vitro and in situ structural studies were conducted on HIV-1 MAL, a recombinant virus 
with a PBS domain of subtype A origin [43,44], and subtype B isolates Lai, HxB2 and NL4-3 [44-47]. 
Although the different isolates display strong sequence homologies, the MAL isolate differs from the 
subtype B isolates by a 23-nucleotide insertion downstream of the PBS (nucleotides 211 to 233, 
underlined in figure 4b) resulting from a partial duplication of the PBS sequence and several point 
mutations (Figure 4b, d). Sequence alignments reveal that 14% of all HIV-1 isolates possess this 
insertion [48]. However, as this insertion is absent from subtype B isolates, which are over-represented 
in the databank, but present in the subtypes and circulating recombinant forms most actively involved 
in spreading of HIV-1, the biological importance of isolates presenting a MAL-like insertion is greater 
than suggested by the databank [48]. These sequence differences account for the different secondary 
structure models proposed by different groups, with a conserved A-stretch located 10 nucleotides 
upstream of the PBS either in an apical loop in the case of MAL (Figure 4b) [44,49] or in an internal 
loop for the Lai, NL4-3 or HxB2 isolates [39,44-47,50-52] (Figure 4d). Notably, the secondary 
structures shown in Figure 4b and 4d, first deduced from classical in vitro probing studies, are 
supported by recent experiments conducted on viral RNA directly modified within infected cells [45-
48].  
4. The Primer/Template Complex 
4.1. From initiation to elongation  
When reverse transcription was tested in vitro using purified natural tRNA3
Lys, a synthetic vRNA 
fragment and purified recombinant RT, it appeared that (-) ssDNA synthesis proceeds in a two step 
manner [53-56] (Figure 3): 1) an initiation phase, during which RT dissociates rapidly from the 
primer/template duplex, corresponds to the slow and distributive addition of the first 6 nucleotides. 
Initiation was found to be specific, since non-homologous RTs, like AMV and MLV RTs, did not 
extend the natural tRNA3
Lys primer efficiently; 2) an unspecific elongation phase, where dissociation 
of RT is slow, leading to processive DNA synthesis. During elongation, there is no specific 
recognition between HIV-1 RT and the primer/template duplex and any RT performs in the same 
manner. It was shown that the modified nucleotides of the natural tRNA were required for the 
specificity and efficiency of the initiation step [53-55,57] and that a DNA oligonucleotide strictly 
complementary to the PBS was representative of the elongation step (Figure 3). Such features were 
also demonstrated for HIV-2 [58] and FIV [56], and could be a general characteristic of all 
retroviruses, since there is also evidence from avian and murine retroviruses [59]. Viruses 2010, 2                                       
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4.2. Extended HIV-1 RNA/tRNA3
Lys interactions and their implication in initiation of reverse 
transcription in vitro  
The idea that the PBS is not the sole determinant for primer usage was supported by observations 
from different laboratories. Indeed, transfection of proviral DNA with PBS sequences mutated to be 
complementary to the 3’ end of tRNAs other than the natural tRNA3
Lys yielded HIV-1 viruses with 
dramatically reduced replication kinetics that eventually reverted back to the wild-type PBS sequence 
[60-62]. Notably a similar observation was made with avian viruses [63] but not with murine viruses 
[64,65]. Various intermolecular primer/template interactions in HIV-1 were proposed by different 
groups to modulate the efficiency of reverse transcription in vitro, leading to apparently conflicting 
results. 
Figure 3. Schematic representation of HIV-1 specific initiation (a)  versus unspecific 
elongation (b) of reverse transcription. The vRNA template is represented by a thin grey 
line. The natural tRNA3
Lys primer or an 18 mer DNA primer are in black and the newly 
synthesized DNA is represented by thick blue and red lines representative of the initiation 
and elongation steps of reverse transcription, respectively. In the presence of the natural 
tRNA primer, transition between initiation and elongation occurs after the addition of the 
first 6 nucleotides to the 3’ end of the primer. In the case of the HIV-1 MAL isolate, 
transition is facilitated by the anticodon/A-rich loop interaction upstream of the PBS, 
represented by the close contact between tRNA3
Lys and the vRNA.  
 
 
4.2.1. Two and three-dimensional structures of a representative subtype A initiation complex 
The first in vitro structural data for a tRNA/vRNA duplex were obtained from enzymatic and 
chemical probing on a heat-annealed complex between tRNA3
Lys and a fragment of HIV-1 MAL 
vRNA containing the complete 5’-UTR [66,67]. They revealed intricate intermolecular interactions 
between tRNA3
Lys and viral sequences located upstream of the PBS (Figure 4a-c). An identical 
conformation of the binary complex was observed when the primer was annealed to the vRNA with 
the nucleocapsid protein [68]. The stability of the proposed extended interactions was found to depend 
on the post-transcriptional modifications of tRNA3
Lys [67,69] and on the complementarity between the 
anticodon loop of the primer and the conserved A-rich loop of the vRNA located in the apex of the U5 
stem [66,70]. Viruses 2010, 2                                       
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Figure 4. Secondary structure of the RNA partners of the HIV-1 initiation complex of 
reverse transcription and of the binary primer/template complexes, in the case of the HIV-1 
MAL (representative of a subtype A PBS domain) and subtype B isolates. The regions 
undergoing intra- or intermolecular rearrangements upon formation of the primer/template 
complex are highlighted in various colours. Boxes or sequences of the same color 
represent areas that are base-paired in the binary complex. (a) The human tRNA3
Lys. (b) 
The PBS sub-domain in the free form of the HIV-1 MAL vRNA. (c) The HIV-1 MAL 
vRNA/tRNA3
Lys complex. (d) The PBS sub-domain in the free form of the HIV-1 NL-4.3 
(subtype B) isolate. The PAS and mutations 2L and 2R are indicated. (e) Localization of 
the anti-PAS region of tRNA3
Lys. 
 
 
The NMR structure of a stem-loop containing the A-rich sequence of the MAL isolate revealed that 
the structure of the loop resembles the one of a tRNA anticodon loop, with a non-canonical G-A pair 
closing the loop and a U-turn motif leading to the continuous stacking of 164-AAA-166 onto 
A167 [71]. This pre-stacked structure renders the loop a good candidate for base-pairing, most likely 
with the U-rich anticodon loop of tRNA3
Lys, in the same way as any tRNA anticodon would base-pair 
with messenger RNA. The solution structure of a duplex representative of the A-rich loop/tRNA 
interaction pointed to the importance of base modifications for stabilization of the vRNA/tRNA 
complex, in agreement with previously published work [57,67,69]. Indeed, the thio-group of U34 plays 
a crucial role in the stabilization of the loop-loop interaction that makes helix 6C (Figure 4c), whereas Viruses 2010, 2                                       
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39 contributes to it [72]. Accordingly, in vitro reverse transcription experiments revealed that the 
modified nucleotides of tRNA3
Lys and extended primer-template interactions are required for efficient 
initiation and transition to elongation of reverse transcription respectively [53,57]. 
A three-dimensional model of the MAL vRNA/ tRNA3
Lys /RT ternary complex was proposed, based 
on probing data and footprinting experiments [73]. Strikingly, none of the extended intermolecular 
interactions (helices 3E, 5D and 6C in Figure 4c) are directly recognized by RT. Their assumed role is 
to impose a particular primer/template conformation that correctly places the intermolecular helix 
containing the PBS (helix 7F) and the 3’-OH group of the primer into the RNA-binding cleft of RT. 
Mutational analysis pointed to the three-nucleotide junction between helices 2 and 7F and the 
intermolecular RNA/tRNA interactions forming helix 6C as the most critical elements for efficient 
initiation of reverse transcription (Figure 3c) [44,53]. These results are in keeping with the three-
dimensional model and agree with the idea that the intermolecular interactions impose a precise 
tertiary structure and/or counteract possible inhibitory effects of the vRNA structure that could 
otherwise lead to steric clashes between RT and RNA.  
4.2.2. Secondary structure of tRNA/vRNA complexes representative of subtype B isolates 
Structural probing performed in vitro on vRNA associated to tRNA3
Lys by thermal annealing [48] 
led to the same results as in situ probing on vRNA/tRNA complexes isolated from virions [45,48]. In 
contrast to the subtype A situation, only the interaction involving the PBS could be observed for 
subtype B, with no structural rearrangement accompanying tRNA3
Lys annealing [48]. Recently, two 
studies using the SHAPE technology were performed on genomic vRNA extracted from virions and 
deproteinized. Although they generally gave very similar results, the secondary structure models 
derived from these experiments vary in the PBS region [46,47]. Data from the first publication lead to 
the proposal of two additional primer/template interactions, on top of the PBS interaction: one between 
the A-rich sequence and the U-rich anticodon loop of tRNA3
Lys, the other between the 3’ anticodon 
stem and part of the variable loop and a sequence upstream of the PBS, as suggested by Iwatani and 
co-workers [74]. The second set of data does not account for any primer/template interactions beside 
the one involving the PBS. The difference between the two sets of data may lie in a slightly different 
protocol for virus preparation and deproteinization.  
It was suggested that in MAL the extended interactions with tRNA3
Lys, which incidentally were also 
confirmed by in situ probing [48], are required to trigger the structural rearrangements generating the 
three-dimensional elements ultimately recognized by RT. These rearrangements would be necessary to 
prevent steric clashes. The absence of structural rearrangements in NL4-3/HxB2 was accounted for by 
the fact that essential structural elements such as helices 1 and 2 and the three single-stranded 
nucleotides at the junction between the PBS helix and helix 2, found in the MAL RNA/ 
tRNA3
Lyscomplex, preexist in subtype B vRNA prior to tRNA3
Lys annealing [44,48] (Figure 4c, d). In 
line with this interpretation, an 18-mer RNA oligonucleotide complementary to the PBS efficiently 
primed reverse transcription of NL4-3/HxB2 RNAs [75,6], but that of MAL RNA [53]. 
The possible role of the A-rich loop was nevertheless investigated in the two very similar HxB2 and 
NL4-3 RNAs, leading to unexpectedly divergent observations. The deletion of the AAAA sequence 
severely reduced initiation of reverse transcription [75,76]. However, the final amount of (-) ssDNA Viruses 2010, 2                                       
 
 
222
synthesis was found to be only modestly decreased, presumably due to the elimination of strong 
pausing sites after the addition of 11 to 14 nucleotides [76]. This deletion was also reported to have 
only a modest effect on (-) ssDNA synthesis in the presence of NCp [77]. By contrast, an AAAA to 
UUUU substitution on NL4-3 RNA was found to enhance the efficiency of (-) ssDNA synthesis, in the 
absence and presence of NCp [74]. It is possible that the deletion of the AAAA sequence induces 
structural perturbation of primer/template complex, thus explaining these differences. 
4.2.3. The PAS/anti-PAS interaction 
An alternative intermolecular interaction between the TC loop in tRNA3
Lys and a conserved 8-
nucleotide sequence within helix 1, downstream of the PBS (123GACUCUGG130) (Figure 4d, e), 
termed the Primer Activation Signal (PAS), was proposed to be important for regulated reverse 
transcription [43,50]. Mutation of the PAS sequence (mutant 2L, Figure 4d) strongly reduced the 
efficiency of the initiation of reverse transcription, while mutation of the opposite strand (mutant 2R, 
Figure 4d) enhanced reverse transcription, both in vitro and using virion-extracted primer/template 
complexes. The latter effect is most likely due to disruption of helix 1 and exposure of the PAS 
sequence [43,50]. The double mutation (2LR), theoretically restoring base-pairing, did not sustain 
efficient reverse transcription, suggesting that the sequence rather than the helical structure is 
important for reverse transcription. It was also shown that the efficiency of reverse transcription could 
be modulated by PAS mutations engineered to strengthen or weaken the interaction with the anti-PAS 
[78]. However these mutations not only interfere with the PAS/antiPAS interaction, but also affect the 
stability of helix 1 that is directly recognised by RT [44,48]. Recently, other sequences downstream of 
the PBS were reported to regulate initiation of reverse transcription in vitro, by affecting the 
accessibility of the PAS motif [79]. Finally, attempts to complement, in vitro, the 2L mutation in the 
PAS sequence by a corresponding change in the antiPAS of a synthetic tRNA3
Lys primer (2L- 
tRNA3
Lys) were not successful [78]. The similarity between the PAS/anti-PAS interaction in HIV-1 
and the interaction proposed for Rous sarcoma virus genomic RNA and its tRNA
Trp primer [80], 
together with the conservation of the PAS sequence among several retroviruses, led to the proposal 
that retroviral reverse transcription could be regulated by a common mechanism [78]. 
These conclusions were challenged by another study conducted on the same HxB2 vRNA variants 
[81]. In agreement with the previous studies [43,50], in vitro (-) ssDNA synthesis was severely 
affected by mutation 2L and was not restored by the double mutation 2LR, whether tRNA3
Lys or an 18-
mer RNA oligoribonucleotide complementary to the PBS were used as primers. However, this 
reduction was correlated with enhanced pausing, while the initial rate of primer extension was 
unaffected [81]. On the contrary to previous results [43,50], mutation 2R was found to reduce (-) 
ssDNA synthesis, with a five-fold decrease of the initial rate of primer extension [79]. This 
observation is consistent with in vitro data from another group indicating that efficient tRNA3
Lys-
primed (-) ssDNA synthesis required the 24 nucleotides downstream of the PBS (which include the 
sequence concerned by mutation 2R) [74].  
Chemical probing on wild-type and mutant vRNAs supported the existence of base-pairing forming 
helix 1 and its disruption by mutation 2L [50,81]. However, the effect of mutations on RNA structure 
could not be unequivocally interpreted, as there was no clear evidence that the wild type secondary Viruses 2010, 2                                       
 
 
223
structure was restored in mutant 2LR [81]. Structural rearrangements were also suggested in mutants 
2L and 2R, keeping open the question of whether the reverse transcription defects might be attributed 
to incorrect folding or to the inability to form the PAS/antiPAS interaction [81]. 
4.2.4. The interaction involving the tRNA anticodon stem and the variable loop 
As mentioned above, efficient (-) ssDNA synthesis was shown to require the 24 nucleotides 
downstream of the PBS when using NL4-3 vRNA template and tRNA3
Lys as a primer [74]. The same 
template sequence was also found to be required with an all-RNA 18-mer primer (R18) 
complementary to the PBS or a chimeric primer containing nine deoxyribonucleotides at the 3’ end, 
but not with a DNA primer or a chimeric primer containing deoxyribonucleotides at the 5’ end. This 
was consistent with the fact that (-) ssDNA synthesis is sensitive to the nature of the helical 
conformation of the primer/template duplex [53-55,82]. Interestingly, the requirement for the 
downstream sequence is alleviated by the nucleocapsid protein (NCp) when natural or unmodified 
tRNA3
Lys, but not the R18 primer, were used as primers [74]. Remarkably, mutation of nucleotides 
142-148 complementary to the 3’ strand of the anticodon stem and the variable loop of tRNA3
Lys 
(Figure 4d, e) abolished the rescue by NCp in the absence of the downstream sequence [74]. Thus, 
NCp seems to be able to increase reverse transcription by facilitating extended interactions between 
tRNA3
Lys and upstream template sequences. These results address the question of the conditional 
requirement for highly conserved sequences forming helix 1, depending on the presence or absence of 
NCp. A possible explanation given by Iwatani et al. [74] is that helix 1 (Figure 4d) might be important 
for the maintenance of a structure stabilizing the initiation complex in the absence of NCp.  
4.3. Biological significance of extended HIV-1 RNA / tRNA3
Lys interactions for virus replication  
The importance of extended interactions for viral replication was addressed by two different 
approaches: 1) sequence deletions containing the elements proposed to participate to these 
interactions, and 2) investigation of HIV-1 variant viruses that use a non-self tRNA primer for reverse 
transcription.  
4.3.1. HIV-1 viruses carrying sequence deletions upstream and downstream of the PBS  
The deletion of the A-rich loop (169AAAA172) in HxB2 RNA resulted in diminished levels of 
infectivity and reduced synthesis of viral DNA [75]. After long-term culture, 167GG168 were 
substituted by two As, restoring wild-type reverse transcription and replication levels [73]. These 
results argued in favour of the importance of the conserved A-rich loop in HIV-1 replication. Besides, 
an earlier study showed that a 26-nucleotide deletion in the 3’ part of the U5 region (∆153-179) of 
NL4-3 vRNA produced a severe defect in infectivity. However, the deletion was found to affect 
integration but did not impair viral DNA synthesis in acutely infected cells, despite the absence of the 
A-rich sequence. This study also indicated that deletion of a 25-nucleotide fragment adjacent to the 
previous one (∆127-152) had no detectable effect on virus replication [81]. Incidentally, this deletion 
contains seven nucleotides proposed to interact with the 3’ strand of the anticodon stem and variable 
loop of tRNA3
Lys, and six of the eight nucleotides of the PAS sequence [83] (Figure 4).  Viruses 2010, 2                                       
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4.3.2. HIV-1 variant viruses that use a non-self tRNA primer for reverse transcription 
Evidence for a role of the A-rich loop/anticodon interaction was brought by experiments showing 
that HIV-1HxB2 could replicate by stably utilizing non-cognate tRNAs as primers, provided that the 
PBS and the A-rich loop were simultaneously mutated to match both the 3’-end and the anticodon loop 
of the chosen tRNAs. This held true for tRNA
His [84-86], tRNA
Met [87,88], and tRNA1,2
Lys [89]. These 
studies, together with the A-loop deletion (see above), pointed to the biological importance of the A-
rich sequence. However, the results might be biased by the presence of overlapping sequences 
important for other functions, like integration [83,90,91]. It was also proposed that mutations of the A-
rich loop allowed stable usage of non-cognate tRNAs by disfavouring tRNA3
Lys, rather than favouring 
alternate primers [92]. In addition, mutated viruses rapidly acquired additional mutations that 
improved their replication efficiencies [85-89,93], suggesting that the A-rich sequence/anticodon-loop 
interaction may not be sufficient for optimal initiation of reverse transcription. The replication defect 
of these viruses might also be linked to their inability to selectively package their non-self tRNA 
primers [94]. 
Nevertheless, a direct correlation between the evolution of mutants using tRNA
His in cell culture 
[85,86,93], their efficiency in initiating reverse transcription in vitro, and the structure of the 
primer/template complex was observed [95]. Indeed, viruses that acquired additional adaptive 
mutations allowing a more stable interaction with the tRNA primer replicated more rapidly and 
displayed nearly wild-type levels of reverse transcription in vitro [85,86]. In addition, probing 
experiments indicated that the mutated A-rich loop forms stable interactions with tRNA
His only in the 
presence of these adaptive mutations [95].  
Attempts were also made to switch the tRNA primer usage by mutating the PAS sequence. In short 
term cultures, viruses containing the PBS-PAS double mutations introduced to enforce the use of non-
self primers tRNA
Pro or tRNA1,2
Lys replicated more poorly than viruses with mutations in the PBS 
alone [96]. This observation is in line with in vitro experiments indicating that tRNA1,2
Lys primed 
reverse transcription of an HxB2 RNA template containing the same PBS-PAS double mutation with 
only ~5 % efficiency compared to the wild-type situation [78]. However, when using primer/template 
complexes extracted from virions, the PBS-PAS double mutation restored tRNA1,2
Lys extension to wild 
type levels [79]. The origin of the difference in the effects of these mutations when using either in vitro 
annealed primer/template or primer/templates extracted from virions is unclear. 
Multiple independent virus evolution experiments selected one PBS variant that was able to stably 
utilize tRNA1,2
Lys and restored high replication rates [96]. This mutant contained a second site 
mutation in the PAS sequence (U126C) that might stabilize the PAS/anti-PAS interaction by 
converting a G-U pair into a G-C pair [96]. Another second site mutation was identified within the RT 
gene (G3600A) that was responsible for a G490E change in the RNase H domain. Both mutations 
improved the replication capabilities of the mutated virus but only the U126C mutation was able to 
prevent reversion to the wild-type PBS [96]. 
Upon prolonged culture of a virus with the wild type PBS and a mutated PAS sequence, revertant 
viruses that partially overcame the reverse transcription defects were selected [43]. Interestingly, 
revertant viruses all acquired a single nucleotide substitution (C150U) that did not restore the PAS Viruses 2010, 2                                       
 
 
225
sequence but stimulated elongation of reverse transcription [43]. This observation fits with the 
proposal that mutations in the PAS affect elongation of reverse transcription rather than initiation [81]. 
The inability of HIV-1 to accommodate a non-self tRNA primer by substituting the PBS alone 
undoubtedly demonstrates the importance of additional interactions for the initiation of reverse 
transcription: MLV, for which no additional interactions have been described [97] easily utilises 
different tRNAs as primers [65], while avian sarcoma virus, for which an interaction between U5 and 
the TC loop has been proposed [80], does not [98]. Incidentally, HIV-1 has been shown to 
infrequently use tRNA5a
Lys as primer [99]; this tRNA only differs from tRNA3
Lys by one base-pair in 
the acceptor stem and has the potential to interacts with both the viral A-rich loop and the PAS 
sequence. 
4.3.3. Reaching a consensus? 
Although the large collection of findings reviewed above provide evidence that the 
complementarity between the PBS sequence and the 3’ part of the primer tRNA is not sufficient to 
determine primer usage, it is difficult to unambiguously rationalize the existence of precise additional 
interactions. The origin of apparent discrepancies is probably multiple and reflects the high complexity 
of the process. The most obvious explanation arises from (i) the existence of biases such as the nature 
of the strains used, (ii) the experimental parameters and tools utilised and (iii) unexpected effects of 
mutations. In particular, RNA mutations may interfere with a variety of steps other than the targeted 
one during the replication cycle. In addition the source of the interference can be direct (i.e., directly 
altering a binding site) or indirect (i.e., by triggering an undesired conformation that becomes inactive 
or induces a steric conflict). Even though a lot of publications already addressed the question of the 
structure of the complex mediating initiation of reverse transcription, several additional studies might 
be envisaged. For instance, whereas many detailed kinetic studies have been performed in vitro on the 
HIV-1 MAL isolate, in vivo studies of mutations affecting the proposed structure are yet to be 
performed. Similarly, the effects of mutations affecting the proposed PAS/anti-PAS interaction on the 
kinetics of reverse transcription have never been studied in infected cells. 
The proposed mutually exclusive interactions might proceed transiently and be required at different 
steps of the replication cycle. Nevertheless, the results collected from experiments designed to probe 
the structure of subtype A and subtype B vRNA/tRNA complexes undoubtedly reveal an unexpected 
structural versatility of the HIV-1 initiation complex. The extraordinary plasticity of the vRNA and its 
capacity to adapt to a variety of constraints, in particular those imposed by mutations, offers the virus 
several solutions to precisely match RT and the viral RNA/tRNA primer complex in order to 
efficiently promote reverse transcription. As an example, the absence of interaction between the A-rich 
loop of NL4-3 and HxB2 vRNAs and the anticodon loop of tRNA3
Lys is at variance with both in vitro 
and ex vivo data showing that a double mutation of the PBS and A-rich loop allowed the use of 
tRNA
His as a primer for reverse transcription. It was proposed that in this case the loop-loop interaction 
was used to compensate a negative contribution of tRNA
His [95]. This would imply that all tRNAs are 
not equally suited to prime reverse transcription, in agreement with a study comparing non cognate 
tRNAs [100].  Viruses 2010, 2                                       
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4.4. The case of HIV-2  
In the case of HIV-2, in vitro structural studies led to the proposal of a secondary structure in which 
most of the nucleotides of the vRNA are base-paired, with the noticeable exception of the PBS 
sequence, in which only 3 out of 18 nucleotides are involved in base-pairing interactions [101]. In this 
model, the PBS sequence is preceded by a long hairpin, containing two A-stretches in both an apical 
and an internal loop [101,102] (Figure 5a).  
On the contrary to the situation with HIV-1 MAL, formation of the binary complex does not 
involve any intermolecular rearrangements [102] (Figure 5). However, similarly to HIV-1 MAL, the 
U-rich anticodon loop of tRNA3
Lys interacts with an A-rich loop upstream of the PBS, while 
nucleotides of the 5’ part of the TC stem interact with nucleotides in the U5 sequence upstream of 
the PBS [102], in a way reminiscent of the HIV-1 PAS/anti-PAS interaction (Figure 5). 
Figure 5. Secondary structure models of the HIV-2 vRNA (a) and of the vRNA/tRNA3
Lys 
complex (b). The tRNA is in red and the vRNA in black. 
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5. Mechanism of primer tRNA annealing to HIV-1 RNA by the viral nucleocapsid protein 
As described above, tRNAs are highly structured macromolecules. Formation of the binary 
vRNA/tRNA complex necessitates, at least, the unfolding of the 3D structure of the primer tRNA and 
melting of base-pairings in the acceptor and TC arms. Such a phenomenon does not occur 
spontaneously at 37 °C and numerous studies have identified the viral nucleocapsid protein as the 
required chaperone co-factor [77,103-106] (for a review see [107]). Annealing between the two 
partners of the reverse transcription initiation complex can be achieved either by the NC domain 
within the unprocessed pr55Gag precursor [108-112] or by the mature NC [77,103-106]. Mature NC is 
a small basic protein that exists mainly in two forms, NCp15 and NCp7, the latter being the final 
maturation product. It contains two CCHC zinc-fingers, separated by a short basic linker and flanked 
by N- and C-terminus basic residues [107]. The role of each NC domain in tRNA annealing has been 
the source of some debate but a consensus seems to have been finally reached. It is now accepted that 
although the zinc fingers are required for optimal chaperone activity [113-115], the basic amino-acids 
surrounding the N-terminal zinc fingers are absolutely necessary for the annealing activity 
[104,113,116]. Several groups have been trying to dissect the annealing process, using different 
approaches: terbium cleavages and kinetic studies for the Musier-Forsyth group and detection of base-
pair melting or formation by NMR, in the absence or presence of NC, for the Dardel group. From their 
data, it appears that the first step of hybrid formation is the melting of a small duplex, followed by a 
nucleation step that brings together the sequences to be annealed [114,117]. The basic amino-acids 
flanking the first zinc finger, which do not directly contact the tRNA but strengthen binding, were 
proven to be essential for this process. Even though NMR studies showed that nucleation can occur 
without NCp, this protein dramatically accelerates the process and is strictly required for full 
annealing. The nucleation process could be initiated by the unpaired 3’ CCA of the tRNA [117] and/or 
by the four unpaired bases that form the junction between the acceptor and the TC-stems [114,118]. 
Unwinding of the rest of the double-stranded RNA regions happens thanks to the zinc fingers of NC, 
the structure of which is necessary for most of the specific contacts with tRNA [119]. The zinc fingers 
are also involved in destabilization of the tertiary TC/D loop interaction [113,120]. 
6. Effects of the restriction factors APOBEC-3G/3F and of the viral infectivity factor (Vif) on the 
early steps of reverse transcription 
APOBEC-3G (A3G; APOlipoprotein B m-RNA-Editing enzyme, catalytic polypeptide 3G) and 
A3F are restriction factors expressed in primary human T-cells, macrophages and monocytes, which 
are the main reservoir of HIV-1 in humans, as well as in some lymphocyte-derived cell lines. The viral 
infectivity factor (Vif) neutralizes these restriction factors and is required for HIV-1 replication in 
these so-called “non-permissive” cells (for a review, see [121]). A3F and A3G are cytidine deaminases 
[122] that introduce C to U transitions during (-) strand DNA synthesis, leading to G to A mutations in 
the (+) strand DNA which are deleterious to the virus. It was long believed that the antiviral activity 
associated with APOBEC proteins was entirely due to cytidine deamination [121,123,124]. However, 
the basis for a possibly more complex mechanism were already laid by early observations by 
Dettenhoffer and Yu [125] who highlighted a more than 50% decrease in the tRNA3
Lys-primed reaction 
in vif (-) virions produced from non-permissive cells. Accordingly, the antiviral activity of A3G has Viruses 2010, 2                                       
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been correlated to the capacity of this protein to inhibit the synthesis of short reverse transcripts, rather 
than to hypermutation [126]. Indeed, a number of studies showed that enzymaticaly inactive A3G and 
A3F are able to inhibit HIV-1 reverse transcription, even though the deaminase activity is required for 
optimal anti-HIV-1 activity of these restriction factors [121].  
A possible link with early steps of reverse transcription was suggested when an interplay between 
NC, A3G and RT was observed. Indeed, the NC domain of Gag is not only required for primer tRNA 
packaging and annealing, but also for A3G incorporation into the viral particles [127]. In addition, in 
vitro experiments indicated that A3G interacts with NC to inhibit tRNA annealing to the vRNA, and 
hence decreases priming efficiency by >50% in vitro and in cell culture [128,129]. The same inhibition 
features were described for A3F [130]. In protease (-) viruses, A3G does not inhibit the Gag-driven 
tRNA annealing to the PBS sequence. This hybridisation generates a vRNA/tRNA complex that is less 
stable than the complex formed later on, in the presence of mature NCp7 [110]. The initial “weak” 
vRNA/tRNA complex, formed by Gag, can be “rescued” in vitro into the mature complex by exposure 
to NCp7, and that rescue is inhibited by A3G [110]. The hypothesis developed by the authors is that 
the binary vRNA/tRNA complex formed in the presence of Gag, during the budding step, could be 
transformed by mature NCp7, within the mature virion, into a more solid complex that undergoes 
reverse transcription. In this context, the observation that Vif has an RNA chaperone activity and is 
able to promote annealing of tRNA3
Lys to the PBS in vitro may provide an additional mechanism by 
which Vif counteracts the antiviral activity of A3G and A3F [131]. However, inhibition of tRNA 
annealing by A3G was not confirmed by the other groups [132,133]. These studies suggested that A3G 
inhibits the elongation phase of reverse transcription, even in the absence of cytosine deaminase 
activity, but not tRNA3
Lys annealing, both in vitro [133] and when reverse transcription was performed 
in melittin-permabilized purified virions [132].  
In conclusion, it has become clear recently that the reduced accumulation of viral DNA in HIV-1 
infected cells in the absence of Vif is not only related to the cytidine deaminase activity of A3G and 
A3F but is likely linked to the inhibition of the early steps reverse transcription. Whether the annealing 
of tRNA3
Lys to the PBS and/or the initiation of reverse transcription are directly affected by these 
restriction factors awaits further experimental confirmation. 
7. Spatio-temporal regulation of reverse transcription 
7.1. In producer cells  
Where and when exactly reverse transcription is initiated has been a debate for some time. Even 
though tRNA extended by two nucleotides has been isolated from purified virions [134], it was 
commonly accepted that the entire reverse transcription process could not take place within virions due 
to an insufficient dNTP concentration for completion of the reaction [135,136]. However, it was 
recently shown that low levels of complete reverse transcription products of genomic and spliced HIV-
1 RNA could be detected in viral particles[137]. 
The chaperone NC protein not only plays a crucial role in annealing the primer tRNA to the vRNA, 
but is also involved in the control of the timing of reverse transcription during the late phase of the 
HIV-1 replication cycle. The latter property of NC was discovered recently, when Mougel and co-
workers deleted one or both zinc fingers of NCp, leading to high levels of viral DNA packaged into Viruses 2010, 2                                       
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viral particles that became non infectious [138] (Figure 6). It was demonstrated that DNA synthesis 
was not due to natural endogenous reverse transcription, but was indeed the first example of premature 
reverse transcription taking place during the late step of the replication cycle, in the producer cell. This 
result was confirmed by single mutations in one or the other zinc finger, as well as disruption of the 
NC/RNA interactions by mutation of the N-terminal basic residues of NCp, which all yielded late 
reverse transcription products [139,140]. Hence, wild type viral NC protein is required to ensure the 
correct timing of reverse transcription, since early reverse transcription during the late phase of the 
replication process, in the cytoplasm prior to budding, is detrimental to viral replication (Figure 6). 
Intramolecular base-pairing of the PAS sequence, which could modulate its interaction with tRNA3
Lys, 
might play a similar role [43,50]. 
Figure 6. Schematic representation of the temporal regulation of reverse transcription in 
producer and target cells.  
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7.2. In target cells 
Efficiency of reverse transcription is most likely also controlled during the early steps of the 
replication cycle, after viral entry. It was long believed that entry was immediately followed by an 
uncoating process that liberates the Reverse Transcription Complex (RTC) into the cytoplasm. Recent 
data from Charneau’s group suggested that the viral core remains assembled after entry and that 
reverse transcription takes place within that confined environment, keeping all the components tightly 
associated and moving along the microtubule network towards the nuclear compartment [141]. 
Uncoating, triggered by the synthesis of the central flap, would occur only after completion of reverse 
transcription and in close proximity to the nuclear pores [141,142]. The RTC would then transform 
into a pre-integration complex that is translocated through the nuclear membrane [141,142].  
Recent work from the group of D. Harrich has shown that cellular factors stimulate reverse 
transcription in the target cells [143] (Figure 6). Unexpectedly, recent data from the same group 
showed that the early steps of reverse transcription are negatively regulated in the target cells and that 
suppression of this negative control is detrimental to HIV-1 replication (Figure 6) [144]. Thus, there is 
increasing evidence that initiation of reverse transcription is temporally regulated, both in the producer 
and in the target cells. 
8. Initiation of reverse transcription as a drug target 
All inhibitors that target the HIV-1 replication cycle have led to the development of resistance and 
this is true also for reverse transcription inhibitors. In the case of nucleoside analogues of reverse 
transcription (NRTI), resistance occurs either via increased discrimination of the NRTI against the 
natural dNTP or by phosphorolytic excision, the reverse reaction to polymerization, of the chain-
terminating analogue [145-148]. Interestingly, it has been shown that AZT, the first and still one of the 
main NRTIs used in combination therapies, cannot be removed by phosphorolysis or ATP-lysis during 
the initiation phase of reverse transcription, by either wild type [149] or AZT-resistant RT [150]. The 
most likely explanation for this phenomenon is that the structure of the active site of RT containing the 
vRNA/tRNA complex is distorted and does not permit removal of the chain terminator in the same 
way as a for DNA/RNA or DNA/DNA hybrids. This makes the initiation complex a very interesting 
target for the development of specific inhibitors.  
RNA, RNA/RNA and RNA/protein complexes can be targeted by small molecule (for review see 
[151]). The group of F. Dardel has pursued the idea of finding small molecules that could bind the 
primer tRNA3
Lys and hence destabilize the tRNA3
Lys/vRNA initiation complex. An NMR screen, based 
on high selectivity, was used and three short peptides were selected, one of them interacting with 
tRNA3
Lys with a 2 mM dissociation constant. All three peptides were found to recognize the 3D 
structure of the D-stem and loop of tRNAs [152]. Compounds were further optimized for tRNA3
Lys 
binding [153,154]; their effect on initiation of reverse transcription needs now to be tested. 
The strict requirement for the PBS sequence for all HIV-1 isolates and the importance of the A-rich 
loop for initiation of reverse transcription [44,53,66] led to the development of PNA antisense 
oligonucleotides [155,156] or 2’-O-methyl-antisense oligonucleotides [157] targeting the PBS and 
PNAs targeting the PBS together with the upstream A-rich loop [158] or the A-rich loop only [159]. 
All the above-cited antisense oligonucleotides strongly inhibited viral replication as well as initiation Viruses 2010, 2                                       
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of reverse transcription in vitro and in endogenous reverse transcription assays in the case of PNAs. 
The potential of PNA molecules as candidates for the development of new drugs was also emphasized 
by the fact that their uptake is efficient in the presence of a membrane-transducing (MTD) peptide, 
with IC50 for inhibition of viral replication in the range of 0.5 to 0.75 µM [156]. Moreover, MTD 
peptide conjugates of PNAs also diplay virucidal activity [156].  
RNA interference could also be a promising tool for antiviral therapy in general and anti-HIV 
therapy in particular [160-162]. The use of a combinatorial approach for shRNA therapy did yield 
some success in generating shRNA sequences that inhibit viral replication effectively [163]. However, 
although it was shown that viral escape was reduced when highly conserved sequence were 
targeted [164], targeting the PBS sequence using this strategy has not been successful [165]. 
9. Conclusions 
Like most steps in HIV replication, initiation of reverse transcription has been the subject of a very 
large number of in vitro and ex-vivo studies.  
The mechanisms allowing selective packaging of the tRNA3
Lys primer inside the viral particles are 
now well understood. Our understanding of the tRNA3
Lys annealing process mediated by the Gag 
precursor and the subsequent maturation of the initiation complex by mature NCp7 also significantly 
improved. New questions regarding tRNA3
Lys annealing emerged from the observations that A3G and 
A3F may inhibit this process. However, these findings have been questioned and await further 
confirmation. In the same context, the ability of Vif to replace NCp7 in the annealing reaction, and 
thus to potentially act as a counteracting factor to A3F and A3G, has been demonstrated in vitro but 
remains to be assessed in vivo.  
Once the binary vRNA/tRNA3
Lys complex is formed, synthesis of the (-) strand strong stop DNA 
proceeds in two phases, initiation which corresponds to the addition of the first 6 nucleotides to the 
tRNA primer, and elongation, both of which have been well characterized from the enzymology point 
of view. On the contrary, the intermolecular interactions between the viral RNA and tRNA3
Lys taking 
place during this process have been a subject of debate and controversy. The structural versatility of 
the PBS region of the HIV genomic RNA, which has been shown to adopt different structures in 
different isolates, might explain some of the discrepancies. Moreover, some differences between 
experiments published by different laboratories could also arise from the fact that certain RNA 
conformations, even though important, are transient and/or that mutant RNAs may adopt a alternative 
structure not reflecting the wild-type situation.  
Finally, one of the recent and fascinating advances in the field concerns regulation of reverse 
transcription, in space and in time. Indeed, it seems clear that tight negative regulation of reverse 
transcription in producer cells is crucial for the infectivity of the virus, but also that a controlled 
initiation of reverse transcription process in infected cells is important for proper replication.  
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